In our study, we defined an inflammatory response-based scoring (covering CNTNAP1, COL7A1, CRABP2, EIF4EBP1, ELN, NUMBL, PALLD, and TIMP1) called IRscore for individual ccRCC patients, which enabled to precisely predict patient survival and estimate anti-PD-L1 therapy efficacy. The gene discussed is EIF4EBP1; the disease is nonpapillary renal cell carcinoma.